WO2003003971A3 - Utilisation d'agents antidiabetiques pour fabriquer un medicament ayant un effet cicatrisant - Google Patents
Utilisation d'agents antidiabetiques pour fabriquer un medicament ayant un effet cicatrisant Download PDFInfo
- Publication number
- WO2003003971A3 WO2003003971A3 PCT/FR2002/002124 FR0202124W WO03003971A3 WO 2003003971 A3 WO2003003971 A3 WO 2003003971A3 FR 0202124 W FR0202124 W FR 0202124W WO 03003971 A3 WO03003971 A3 WO 03003971A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- medicine
- making
- antidiabetics
- cicatrizing
- cicatrizing effect
- Prior art date
Links
- 230000003178 anti-diabetic effect Effects 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 abstract 1
- 102000004366 Glucosidases Human genes 0.000 abstract 1
- 108010056771 Glucosidases Proteins 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 102000023984 PPAR alpha Human genes 0.000 abstract 1
- 229940123464 Thiazolidinedione Drugs 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 230000003914 insulin secretion Effects 0.000 abstract 1
- 229950004994 meglitinide Drugs 0.000 abstract 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 abstract 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- 150000001467 thiazolidinediones Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002319381A AU2002319381A1 (en) | 2001-06-20 | 2002-06-19 | Use of antidiabetics for making a medicine with cicatrizing effect |
US10/479,615 US20040147430A1 (en) | 2001-06-02 | 2002-06-19 | Use of antidiabetics for making a medicine with cicatrizing effect |
DE60216453T DE60216453T2 (de) | 2001-06-20 | 2002-06-19 | Verwendung von antidiabetika zur herstellung eines vernarbungsfördernden arzneimittels |
DK02748965T DK1397124T3 (da) | 2001-06-20 | 2002-06-19 | Anvendelse af diabetesmidler til fremstilling af et lægemiddel med helende virkning |
EP02748965A EP1397124B1 (fr) | 2001-06-20 | 2002-06-19 | Utilisation d'agents antidiabetiques pour fabriquer un medicament ayant un effet cicatrisant |
CY20061101738T CY1105822T1 (el) | 2001-06-20 | 2006-12-04 | Χρηση αντιδιαβητικων παραγοντων για την κατασκευη ενος φαρμακου που εχει επουλωτικη δραση |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29919601P | 2001-06-20 | 2001-06-20 | |
FR0108130A FR2826278B1 (fr) | 2001-06-20 | 2001-06-20 | Utilisation d'agents antidiabetiques pour fabriquer un medicament ayant un effet cicatrisant |
FR01/08130 | 2001-06-20 | ||
US60/299,196 | 2001-06-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003003971A2 WO2003003971A2 (fr) | 2003-01-16 |
WO2003003971A3 true WO2003003971A3 (fr) | 2003-12-04 |
Family
ID=26213059
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2002/002124 WO2003003971A2 (fr) | 2001-06-02 | 2002-06-19 | Utilisation d'agents antidiabetiques pour fabriquer un medicament ayant un effet cicatrisant |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1397124B1 (fr) |
AT (1) | ATE346601T1 (fr) |
AU (1) | AU2002319381A1 (fr) |
CY (1) | CY1105822T1 (fr) |
DE (1) | DE60216453T2 (fr) |
DK (1) | DK1397124T3 (fr) |
ES (1) | ES2275889T3 (fr) |
WO (1) | WO2003003971A2 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2277910A1 (fr) | 2001-12-21 | 2011-01-26 | Human Genome Sciences, Inc. | Protéines de fusion d'albumine |
DE10214506A1 (de) * | 2002-04-02 | 2003-10-16 | Beiersdorf Ag | Verwendung von Desoxynojirimycin und dessen Derivaten zur Behandlung und Prophylaxe degenerativer Hautzustände |
GB0303600D0 (en) * | 2003-02-17 | 2003-03-19 | Glaxo Group Ltd | Novel therapeutic method and compositions |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3072527A (en) * | 1959-07-01 | 1963-01-08 | Horner Frank W Ltd | Use of tolbutamide in the treatment of acne |
FR2213778A1 (en) * | 1973-01-16 | 1974-08-09 | Voorhees John | Adrenergics or hypoglycaemics for relieving skin disorders - e.g. psoriasis, dermatitis, skin carcinoma and acne in human beings |
US4131652A (en) * | 1977-06-22 | 1978-12-26 | Deluccia Charles R | Medicinal skin cream for psoriasis and method |
US5145679A (en) * | 1989-10-05 | 1992-09-08 | Hinson Joan B | Topical emollient for prevention and treatment of circulatory induced lesions |
WO1993008815A1 (fr) * | 1991-10-28 | 1993-05-13 | Cytoven | Compositions pharmaceutiques dipeptidiques et leurs procedes d'utilisation |
WO1998032429A2 (fr) * | 1997-01-23 | 1998-07-30 | The University Of Liverpool | Agonistes, antagonistes et effecteurs du recepteur p2, agissant sur la liberation d'atp endogene |
WO1998058658A1 (fr) * | 1997-06-23 | 1998-12-30 | The Research Foundation Of State University Of New York | Procede therapeutique destine a traiter le diabete sucre |
JP2000212191A (ja) * | 1999-01-26 | 2000-08-02 | Sankyo Co Ltd | リン酸誘導体 |
WO2001021159A2 (fr) * | 1999-09-17 | 2001-03-29 | Novartis Ag | Procede pour traiter des troubles metaboliques, en particulier le diabete, ou une maladie ou un etat associe au diabete |
FR2802814A1 (fr) * | 1999-12-23 | 2001-06-29 | Aventis Pharma Sa | Association de deoxyfructosazine et d'un antidiabetique de la famille des sulfonylurees |
WO2001076650A1 (fr) * | 2000-04-06 | 2001-10-18 | University Technology Corporation | Compositions et methodes visant a favoriser la cicatrisation |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1133901A (en) * | 1999-10-08 | 2001-04-23 | Novartis Ag | Method of treating metabolic disorders |
AR030379A1 (es) * | 2000-08-22 | 2003-08-20 | Novartis Ag | Combinaciones |
-
2002
- 2002-06-19 WO PCT/FR2002/002124 patent/WO2003003971A2/fr active IP Right Grant
- 2002-06-19 DK DK02748965T patent/DK1397124T3/da active
- 2002-06-19 EP EP02748965A patent/EP1397124B1/fr not_active Expired - Lifetime
- 2002-06-19 AU AU2002319381A patent/AU2002319381A1/en not_active Abandoned
- 2002-06-19 AT AT02748965T patent/ATE346601T1/de active
- 2002-06-19 ES ES02748965T patent/ES2275889T3/es not_active Expired - Lifetime
- 2002-06-19 DE DE60216453T patent/DE60216453T2/de not_active Expired - Lifetime
-
2006
- 2006-12-04 CY CY20061101738T patent/CY1105822T1/el unknown
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3072527A (en) * | 1959-07-01 | 1963-01-08 | Horner Frank W Ltd | Use of tolbutamide in the treatment of acne |
FR2213778A1 (en) * | 1973-01-16 | 1974-08-09 | Voorhees John | Adrenergics or hypoglycaemics for relieving skin disorders - e.g. psoriasis, dermatitis, skin carcinoma and acne in human beings |
US4131652A (en) * | 1977-06-22 | 1978-12-26 | Deluccia Charles R | Medicinal skin cream for psoriasis and method |
US5145679A (en) * | 1989-10-05 | 1992-09-08 | Hinson Joan B | Topical emollient for prevention and treatment of circulatory induced lesions |
WO1993008815A1 (fr) * | 1991-10-28 | 1993-05-13 | Cytoven | Compositions pharmaceutiques dipeptidiques et leurs procedes d'utilisation |
WO1998032429A2 (fr) * | 1997-01-23 | 1998-07-30 | The University Of Liverpool | Agonistes, antagonistes et effecteurs du recepteur p2, agissant sur la liberation d'atp endogene |
WO1998058658A1 (fr) * | 1997-06-23 | 1998-12-30 | The Research Foundation Of State University Of New York | Procede therapeutique destine a traiter le diabete sucre |
JP2000212191A (ja) * | 1999-01-26 | 2000-08-02 | Sankyo Co Ltd | リン酸誘導体 |
WO2001021159A2 (fr) * | 1999-09-17 | 2001-03-29 | Novartis Ag | Procede pour traiter des troubles metaboliques, en particulier le diabete, ou une maladie ou un etat associe au diabete |
FR2802814A1 (fr) * | 1999-12-23 | 2001-06-29 | Aventis Pharma Sa | Association de deoxyfructosazine et d'un antidiabetique de la famille des sulfonylurees |
WO2001076650A1 (fr) * | 2000-04-06 | 2001-10-18 | University Technology Corporation | Compositions et methodes visant a favoriser la cicatrisation |
Non-Patent Citations (5)
Title |
---|
CAVALERI F ET AL: "OSSERVAZIONI SULL'IMPIEGO DEGLI IPOGLICEMIZZANTI ORALI IN DERMOPAZIENTI DIABETICI, CON PARTICOLARE RIGUARDO ALL'ASSOCIAZIONE GLIBENCLAMIDE-FENFORMINA (SUGUAN(R))", GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, TURIN, IT, vol. 112, no. 2, March 1977 (1977-03-01), pages 255 - 266, XP000981768, ISSN: 0392-0488 * |
DATABASE WPI Week 200062, 2 August 2000 Derwent World Patents Index; AN 2000-641024, XP002192081, TAKAHASHI ET AL.: "Phosphoric acid derivative" * |
MASCARDO R.N. ET AL: "Glyburide modulates insulin-mediated locomotor response of confluent cell cultures to wounding.", DIABETES, (1987) 36/12 (1476-1482)., XP008000808 * |
MIHAILOVA E V ET AL: "GOOD HEALING EFFECTS OF DI-METHYL SULPHOXIDE AND INSULIN ON NECROBIOSIS LIPODICA DIABETICORUM IN DYPE-1 DIABETES", EUROPEAN JOURNAL OF ENDOCRINOLOGY, SCANDINAVIAN UNIVERSITY PRESS, NO, vol. 130, no. SUPPL 2, 1994, pages 202, XP000981777, ISSN: 0804-4643 * |
VERGER M F ET AL: "L'INSULINOTHERAPIE CONTINUE AMELIORE LA CICATRISATION DES PLAIES DES PIEDS DIABETIQUES", REVUE DE MEDECINE INTERNE, CMR, ASNIERES, FR, vol. 7, no. 2, March 1986 (1986-03-01), pages 127 - 132, XP000981769, ISSN: 0248-8663 * |
Also Published As
Publication number | Publication date |
---|---|
DE60216453T2 (de) | 2007-09-20 |
ATE346601T1 (de) | 2006-12-15 |
DE60216453D1 (de) | 2007-01-11 |
EP1397124A2 (fr) | 2004-03-17 |
EP1397124B1 (fr) | 2006-11-29 |
ES2275889T3 (es) | 2007-06-16 |
DK1397124T3 (da) | 2007-04-02 |
AU2002319381A1 (en) | 2003-01-21 |
WO2003003971A2 (fr) | 2003-01-16 |
CY1105822T1 (el) | 2011-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200300026A1 (ru) | Аналоги глюкагоноподобного пептида-1 | |
DE69327309D1 (de) | Verwendung eines peptids | |
AR022368A1 (es) | Procedimiento para administrar peptidos insulinotropicos | |
AU2003239478A1 (en) | Modified glucagon-like peptide-1 analogs | |
MXPA02012763A (es) | Combinaciones de inhibidores de dipeptidil peptidasa iv y otros agentes antidiabeticos para el tratamiento de diabetes mellitus. | |
WO2003058203A3 (fr) | Analogues de peptide-1 de type glucagon d'extension | |
WO2003053339A3 (fr) | Molecule d'insuline a duree d'action prolongee | |
WO2006121860A3 (fr) | Agonistes vis-a-vis du recepteur peptidique de type glucagon 1 (glp-1) et procedes pharmacologiques d'utilisation | |
WO2002048192A3 (fr) | Glp-1 amide | |
DE68929217D1 (en) | Insulinotropes hormon | |
ATE334718T1 (de) | Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln | |
MY124695A (en) | Novel composition and use. | |
ATE525083T1 (de) | Pharmazeutische zusammensetzung umfassend eine insulinotrope glp-1(7-37) analoge, asp(b28)- insulin, und eine oberflächenaktive verbindung | |
HUP0501192A2 (en) | Glucagon-like peptide-1 analogs | |
WO2003020201A3 (fr) | Pre-melanges de polypeptide glp-1 et d'insuline basale | |
EA199900169A1 (ru) | Применение глюкагоноподобного пептида-1 (glp-1) или его аналогов для устранения катаболических изменений после оперативного вмешательства | |
AU3372595A (en) | Biologically active fragments of glucagon-like insulinotropic peptide | |
NO940436D0 (no) | Forlenget avgivelse av peptider | |
AP2003002755A0 (en) | Guanidinobenzamides as mc4-r agonists | |
EP1634605A3 (fr) | traitement de la dyslipidémie chez un patient souffrant de diabète de type 2 | |
MY155219A (en) | Treatment of diabetes with thiazolidinedione, insulin secretagogue and biguanide | |
WO2003003971A3 (fr) | Utilisation d'agents antidiabetiques pour fabriquer un medicament ayant un effet cicatrisant | |
BG104062A (en) | Treatment of diabetes with thiazolidindion, stimulant of insulin secretion and alpha-glucosidase inhibitor | |
BG104139A (en) | Diabetes treatment with thizolidindion and sulphonylurea | |
AR008025A1 (es) | Combinación farmacéutica de una tiazolidindiona y un secretagogo de insulina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002748965 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10479615 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2002748965 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002748965 Country of ref document: EP |